Suppression of hypoxia-induced excessive angiogenesis by metformin via elevating tumor blood perfusion
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
// Ji-Chang Wang 1, 2, * , Guang-Yue Li 3, * , Ping-Ping Li 2 , Xin Sun 4 , Wei-Ming Li 1 , Yan Li 1 , Shao-Ying Lu 1 and Pei-Jun Liu 2 1 Department of Vascular Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, 710061, P.R.China 2 Center for Translational Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, 710061, P.R.China 3 Department of Science and Technology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, 710061, P.R.China 4 Department of Thoracic Surgery and Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, 710061, P.R.China * These two authors contributed equally to this work and share co-first authors Correspondence to: Pei-Jun Liu, email: liupeijun@mail.xjtu.edu.cn Shao-Ying Lu, email: robertlu@mail.xjtu.edu.cn Keywords: metformin, inhibition of tumor angiogenesis, hypoxia, elevating blood perfusion, HIF-1α Received: April 09, 2017 Accepted: May 09, 2017 Published: May 19, 2017 ABSTRACT The anti-diabetic metformin has been demonstrated to be effective in suppression of tumor progression via multiple mechanisms, in which angiogenic inhibition is involved. Hypoxia is a common feather of malignant tumor and promotes angiogenesis via induction of pro-angiogenic factors. However, the effect of metformin on tumor hypoxia and the association with angiogenic inhibition are still unclear. In the current study, we investigated the effects of metformin on both tumor blood perfusion and hypoxia-induced excessive angiogenesis. In the tumor region adjacent to necrosis, aberrantly excessive angiogenesis resulted from hypoperfusion-induced intense hypoxia and greatly contributed to the high average levels of both microvessel density and vascular branch density. Metformin administration increased the percentage of lectin-perfused vessels and reduced hypoxyprobe-positive area. This metformin-induced amelioration of hypoxia was accompanied by a significant reduction in expressions of both HIF-1α and angiogenesis-associated factors (AAFs). Consequently, inhibited excessive angiogenesis in hypoxic peri-necrotic region was observed in metformin-treated tumor. Further stable knockdown of HIF-1α abrogated hypoxia-induced AAFs in vitro and reduced both microvessel density and area of fitc-conjugated dextran that leaked outside the vascular lumen. Taken together, metformin ameliorated tumor hypoxia and restrained HIF-1α-induced expressions of AAFs through elevating tumor blood perfusion, thus suppressing the excessive tumor angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α
Arany, Z., Foo, S.-Y., Ma, Y., Ruas, J. L., Bommi-Reddy, A., Girnun, G., Cooper, M., Laznik, D., Chinsomboon, J., Rangwala, S. M., et al. (2008) · Nature · doi:10.1038/nature06613 · Cited by 1,054
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells
Isoda, K., Young, J. L., Zirlik, A., MacFarlane, L. A., Tsuboi, N., Gerdes, N., Schönbeck, U., & Libby, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000201938.78044.75 · Cited by 499
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493 · cited 1×
“Epidemiological and experimental studies have revealed that the anti-diabetic metformin was able to reduce risk of various types of cancer [6] and inhibit tumor progression [7].”
BackgroundHiraga, T., Kizaka-Kondoh, S., Hirota, K., Hiraoka, M., & Yoneda, T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2355 · Cited by 242 · cited 1×
“HIF-1α is one of the most critical factors for mediating angiogenesis in hypoxic condition [21, 22].”
BackgroundMetformin and Other Biguanides in Oncology: Advancing the Research Agenda
Pollak, M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0175 · Cited by 240 · cited 1×
“Due to its clinical safety and anti-tumor activities demonstrated by pre-clinical researches [8, 9], researchers are increasingly concerned to understand its anti-tumor potentials.”
BackgroundESFAHANIAN, N., SHAKIBA, Y., NIKBIN, B., SORAYA, H., MALEKI-DIZAJI, N., GHAZI-KHANSARI, M., & GARJANI, A. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.753 · Cited by 120 · cited 1×
“Vessels in tumors treated with vascular promoting agents were reported to be dilated and with leakage [30].”
Background
Cited by
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Li, M., Zhang, X., Wang, M., Wang, Y., Qian, J., Xing, X., Wang, Z., You, Y., Guo, K., Chen, J., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12364 · Cited by 181
“The reasons for this selection were as follows: (1) the evidence presented above suggested that Piezo1 was a pro-angiogenic regulator and mediated matrix stiffnessinduced angiogenesis; (2) VEGF, IGFBP2, and CXCL16 had a common upstream transcription factor hypoxiainducible factor (HIF-1α) [15, 16, 53, 54] and affected…”
BackgroundWang, J.-C., Li, G.-Y., Wang, B., Han, S.-X., Sun, X., Jiang, Y.-N., Shen, Y.-W., Zhou, C., Feng, J., Lu, S.-Y., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1211-2 · Cited by 138
Self-citation
Metadata
- Authors
- Wang, J.-C., Li, G.-Y., Li, P.-P., Sun, X., Li, W.-M., Li, Y., Lu, S.-Y., & Liu, P.-J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-05-19
- Volume
- 8
- Issue
- 43
- Pages
- 73892-73904
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2614231898
- Cited by
- 41
- References
- 8
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.